1月9日，中科通达涨5.01%，截至发稿，报19.50元/股，成交7172.74万元，换手率3.27%，总市值22.69 亿元。中科通达股价已经连续7天上涨，区间累计涨幅13.44%。 资料显示，武汉中科通达高新技术股份有限公司位于湖北省武汉东湖新技术开发区关山大道1号软件产 业三期A3栋10层，成立日期2007年6月8日，上市日期2021年7月13日，公司主营业务涉及通过新一代信 息技术手段,为城市公共安全管理提供专业的信息化服务。主营业务收入构成为：信息化系统开发建设 68.19%，信息化系统运维17.21%，软件开发及销售8.87%，商品销售及其他5.67%，其他(补充)0.06%。 从中科通达十大流通股东角度 数据显示，大成基金旗下1只基金位居中科通达十大流通股东。大成中证360互联网+指数A（002236） 三季度增持13.26万股，持有股数107.5万股，占流通股的比例为0.92%。根据测算，今日浮盈赚取约 99.98万元。连续7天上涨期间浮盈赚取236.5万元。 大成中证360互联网+指数A（002236）成立日期2016年2月3日，最新规模7.88亿。今年以来收益 3.33%，同类排名2554 ...

Group 1: Non-ferrous Metals Sector - The non-ferrous metals sector has seen significant inflows into ETFs, with notable funds like Wanji Industrial Non-ferrous ETF surpassing 10 billion yuan in scale [1][3] - As of January 7, 2026, major non-ferrous metal ETFs received substantial net inflows: Southern Non-ferrous Metal ETF (2.39 billion yuan), Huaxia Non-ferrous Metal ETF (1.44 billion yuan), and Dachen Non-ferrous ETF (0.93 billion yuan) [3] - Factors driving the non-ferrous metals sector include improved supply-demand dynamics and the global trend of "re-industrialization," alongside geopolitical tensions affecting resource supply [1][4] Group 2: Commercial Aerospace Sector - The commercial aerospace sector has also attracted significant investment, with the Yongying Satellite ETF rising by 6.2% and leading the market [5][6] - As of January 7, 2026, the Yongying Satellite ETF and the Zhaoshang Satellite Industry ETF each gained over 1 billion yuan in net inflows since the beginning of the year [6] - The commercial aerospace sector is expected to accelerate in 2026, driven by policy support, IPOs of leading companies, and heightened strategic value due to geopolitical factors [6]

Core Viewpoint - The article highlights the successful IPO of Rebio Biotech (6938.HK), marking it as the first small RNA drug company listed on the Hong Kong Stock Exchange, with an opening price increase of over 23% and a market capitalization of HKD 11.8 billion [2]. Group 1: Company Overview - Rebio Biotech was founded in 2007 by Liang Zicai, who has extensive experience in the small RNA field, having established an independent laboratory for small RNA research in 1998 [6][7]. - The company has developed a comprehensive R&D platform with proprietary technology, successfully advancing multiple products into clinical phase II trials [7]. - Rebio Biotech has established international R&D centers in Kunshan, Beijing, and Gothenburg, Sweden, demonstrating its capability in global clinical development [7]. Group 2: Investment Background - Lenovo Star became one of the earliest institutional investors in Rebio Biotech in 2015, investing USD 1 million in its Series A financing [5][9]. - The investment strategy of Lenovo Star has focused on early-stage technology and healthcare, allowing them to identify and support leading projects in the small RNA drug sector before it gained significant attention [10]. - Over the years, Rebio Biotech has received support from various venture capital and private equity firms, including IDG Capital and Huaxia Fund, contributing to its growth and development [9]. Group 3: Market Context - The small RNA drug sector was initially considered less attractive, with only one drug approved before 2016, but it has since gained momentum following the approval of Biogen's Spinraza [9]. - The article emphasizes the growing interest and investment in the biopharmaceutical industry, particularly in regions like Suzhou, which has become a focal point for biotech investments [11]. - Lenovo Star's approach has evolved to focus on high-quality, cost-effective drugs and services, reflecting a shift in the healthcare investment landscape [12].

Group 1 - The core viewpoint of the news is that Zhuoyi Information's stock has seen a significant increase, with a rise of 5.13% to 99.98 CNY per share, and a total market capitalization of 12.11 billion CNY [1] - Zhuoyi Information, established on May 12, 2008, and listed on December 9, 2019, focuses on cloud computing technology, with its main revenue sources being core firmware for cloud computing devices (35.09%), cloud services (33.64%), and PB business (27.98%) [1] - The company's cloud service segment includes IoT cloud services (22.80%) and government-enterprise cloud services (10.84%), with other supplementary services contributing 3.30% [1] Group 2 - From the perspective of major fund holdings, Dachen Fund has a significant position in Zhuoyi Information, with its Dachen Zhizhen Return Mixed A Fund holding 248,600 shares, representing 2.38% of the fund's net value [2] - The Dachen Zhizhen Return Mixed A Fund has a total size of 636 million CNY and has achieved a year-to-date return of 6.83%, ranking 797 out of 8827 in its category [2] - The fund manager, Du Cong, has been in charge for 5 years and 138 days, with the fund's total assets amounting to 4.436 billion CNY, achieving a best return of 84.85% during his tenure [3]

Group 1 - The core point of the news is that Xiangyu Medical's stock price dropped by 5.01% to 80.50 yuan per share, with a total market capitalization of 12.88 billion yuan as of the report date [1] - Xiangyu Medical, established on March 20, 2002, specializes in the research, production, and sales of rehabilitation medical devices, with its main revenue sources being rehabilitation therapy equipment (67.79%), rehabilitation training equipment (22.13%), and other related products [1] Group 2 - From the perspective of major fund holdings, Dachen Fund has a significant position in Xiangyu Medical, with its Dachen Zhihui Quantitative Multi-Strategy Mixed A Fund holding 9,685 shares, unchanged from the previous period, representing 3.76% of the fund's net value [2] - The Dachen Zhihui Quantitative Multi-Strategy Mixed A Fund has a total asset size of 8.42 billion yuan, with a year-to-date return of 2.37% and a one-year return of 28.86% [2][3]

Core Viewpoint - The active equity funds are experiencing a significant performance surge in 2025, with many funds achieving over 100% returns in the past three years, highlighting the importance of stock selection by fund managers [1][4][12]. Group 1: Three-Year Performance - As of December 31, 2025, over 135 active equity funds achieved returns exceeding 100% over the three-year period from January 1, 2023, to December 31, 2025 [4]. - Among these, 9 funds surpassed 200% returns, with top performers including Dongwu New Trend Value Line (267.92%), Huaxia North Exchange Innovation Small and Medium Enterprises Selection (260.42%), and Dongwu Mobile Internet A (256.05%) [5]. - The majority of high-performing funds are concentrated in the technology sector, benefiting from the tech market trends in 2025 [7][8]. Group 2: Five-Year Performance - For the five-year period from January 1, 2021, to December 31, 2025, 54 flexible allocation mixed funds, 22 equity mixed funds, and 18 actively managed stock funds achieved returns over 100% [12]. - The top five funds in this category include Jinyuan Shun'an Yuanqi Flexible Allocation (259.53%), Dongwu Mobile Internet A (256.09%), and Dongwu New Trend Value Line (251.22%) [13]. - The five-year performance emphasizes the fund managers' stock selection capabilities, with a more diversified investment approach leading to better long-term results [14]. Group 3: Ten-Year Performance - Over the ten-year period from January 1, 2016, to December 31, 2025, the top ten active equity funds achieved returns ranging from 364.83% to 571.91%, with Huashang Advantage Industry A leading at 571.91% [18][17]. - A total of over 440 active equity funds recorded returns exceeding 100% in the ten-year span, with approximately 5% achieving over 300% [21]. - The performance of these funds reflects a mix of concentrated investments in technology and diversified holdings across various sectors [21].

Group 1 - The core point of the article is the significant adjustment in the ETF market, highlighted by the renaming of Huatai-PB's CSI 300 ETF to "CSI 300 ETF Huatai-PB," effective from January 9, 2024, which is the largest stock ETF in the market with an asset management scale exceeding 400 billion yuan [1][3] - This renaming is part of a broader move towards standardization and transparency in the ETF market, as mandated by the revised business guidelines from the Shanghai and Shenzhen Stock Exchanges, requiring all existing ETFs to complete standardized naming by March 31, 2026 [3][4] - The current total scale of China's ETF market has surpassed 6 trillion yuan, with over a thousand products available, indicating a growing complexity for investors in distinguishing between similar ETFs [3][4] Group 2 - Major fund management companies are actively responding to the new naming regulations, with several leading firms already completing the adjustments; for instance, E Fund and Da Cheng Fund have all their existing ETFs named according to the new standards [4] - As of January 1, 2026, data shows that among the top twenty public fund institutions by ETF asset value, many have successfully implemented standardized naming for their ETFs, enhancing clarity for investors [4][6] - Huatai-PB's completion of standardized naming for its ETFs will increase the total number of its ETFs with standardized names to 21, all adopting the suffix "ETF Huatai-PB," thereby strengthening brand recognition [3][4]

中国银河证券基金研究中心发布的《公募基金长期主动股票投资管理能力榜单》，以近三年、近十年双时间维度数据，清 晰勾勒出公募行业主动权益投资的竞争格局：大型老牌基金公司凭借深厚投研积淀与多元布局彰显业绩持久性，中小型机 构则依托灵活调仓优势突出成长性，两类主体各展所长，共同丰富着市场的投资生态。 观察近三年数据，主动股票投资管理的年化收益率门槛显著高于十年期，这一区间成为中小型基金公司的"秀场"。榜单数 据显示，近三年排名前二十的基金公司中，19家均实现了年化收益率超10%的亮眼成绩。其中，淳厚基金以21.51%的超高 年化收益率位居榜首，财通基金、德邦基金等多家中小型机构的年化收益也均突破15%。 | | | | 1.1-2025.12.31) 公募基金主动股票 | | | | --- | --- | --- | --- | --- | --- | | | | | 期末参评 | 期末参评 | 年代三国 | | 排名 | 管理人 | 参评开始日期 | 重金数量 | 基金规模 | 股票投资量速 | | | | | (日) | (亿元) | 收益率 | | | 大成县金 | 1999/7/1 | 74 | 886.6 ...

来源：财报星球 一次"财富黑卡"权益升级，让支付宝面临百万富翁流失危机。 2026年第一天，支付宝官宣"财富黑卡"权益升级。主要升级内容为：新增黑曜卡S1（门槛300万）和S2 （门槛600万），V3用户降为"财富黑卡"中档用户。 在本次权益升级之前，"财富黑卡"V3用户每月可直接领取8.8元话费红包、星巴克咖啡券、100元加油券 等价值约150元的固定权益。权益升级之后，上述"财富黑卡"V3用户原本可以每月直接领取的固定权 益，变成需要按等级发放V钻，再通过V钻兑换。 | 一每月1日系统将根据上一自然月最后一天的财富黑卡等级发放 | | | | --- | --- | --- | | 相应数量的黑卡V钻。各财富黑卡等级相应黑卡V钻可领取数量 | | | | 如下: | | | | 黑卡等级 | 近30天日均资产 | 每月1日可领取黑卡V钻数量(个) | | 咖赢黑卡 VI | 30万(含)-50万 | 160 | | 则富黒卡 V2 | 50万(含)-100万 | 560 | | 則富黑卡 V3 | 100万(含)-300万 | 1560 | | 则喜黑耀卡 51 | 300万(含)-600万 | 6860 ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Shenzhen Deep Science and Technology Co., Ltd. (深科达), which fell by 5.39% to 31.62 CNY per share, with a trading volume of 1.11 billion CNY and a turnover rate of 3.62%, resulting in a total market capitalization of 2.987 billion CNY [1] - Shenzhen Deep Science and Technology Co., Ltd. was established on June 14, 2004, and went public on March 9, 2021. The company specializes in the research, production, and sales of flat panel display production equipment, with its main business revenue composition being 49.90% from flat panel display equipment, 27.02% from semiconductor equipment, 22.49% from core components, and 0.59% from other sources [1] Group 2 - From the perspective of major circulating shareholders, a fund under Dacheng Fund ranks among the top ten circulating shareholders of Deep Science and Technology. The Dacheng CSI 360 Internet + Index A (002236) entered the top ten circulating shareholders in the third quarter, holding 630,800 shares, which accounts for 0.67% of the circulating shares. The estimated floating loss today is approximately 1.1354 million CNY [2] - The Dacheng CSI 360 Internet + Index A (002236) was established on February 3, 2016, with a latest scale of 788 million CNY. Year-to-date returns are 2.31%, ranking 4490 out of 5493 in its category; the one-year return is 48.1%, ranking 1249 out of 4197; and since inception, the return is 238.37% [2] Group 3 - The fund manager of Dacheng CSI 360 Internet + Index A (002236) is Xia Gao, who has a cumulative tenure of 11 years and 37 days. The total asset scale of the fund is 2.494 billion CNY, with the best fund return during the tenure being 230.73% and the worst being -71.74% [3] Group 4 - From the perspective of the fund's top holdings, the Dacheng CSI 360 Internet + Index A (002236) has a significant position in Deep Science and Technology, holding 630,800 shares, which represents 1.07% of the fund's net value, making it the sixth-largest holding. The estimated floating loss today is approximately 1.1354 million CNY [4]